Currently, several inhaled antibody fragments targeting, e.g., thymic stromal lymphopoietin (TSLP), tumor necrosis factor receptor 1 (TNFR-1), and interleukin-13 (IL-13), are under clinical investigation for the treatment of pulmonary diseases, particularly asthma [19]. The gene discussed is TSLP; the disease is asthma.